Annexon Inc (ANNX) - Net Assets
Based on the latest financial reports, Annexon Inc (ANNX) has net assets worth $204.53 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($262.89 Million) and total liabilities ($58.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Annexon Inc (ANNX) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $204.53 Million |
| % of Total Assets | 77.8% |
| Annual Growth Rate | N/A |
| 5-Year Change | -8.74% |
| 10-Year Change | N/A |
| Growth Volatility | 243.65 |
Annexon Inc - Net Assets Trend (2017–2025)
This chart illustrates how Annexon Inc's net assets have evolved over time, based on quarterly financial data. See ANNX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Annexon Inc (2017–2025)
The table below shows the annual net assets of Annexon Inc from 2017 to 2025. For live valuation and market cap data, see Annexon Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $211.65 Million | -27.79% |
| 2024-12-31 | $293.11 Million | +16.98% |
| 2023-12-31 | $250.56 Million | +8.37% |
| 2022-12-31 | $231.19 Million | -0.31% |
| 2021-12-31 | $231.91 Million | -32.64% |
| 2020-12-31 | $344.28 Million | +690.90% |
| 2019-12-31 | $43.53 Million | +14.92% |
| 2018-12-31 | $37.88 Million | +181.97% |
| 2017-12-31 | $-46.21 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Annexon Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 87029600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $149.00K | 0.07% |
| Other Comprehensive Income | $-29.00K | -0.01% |
| Other Components | $1.13 Billion | 533.39% |
| Total Equity | $211.65 Million | 100.00% |
Annexon Inc Competitors by Market Cap
The table below lists competitors of Annexon Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BEIJ.JINGNENG CL.ERG.HYC1
F:BJ6
|
$741.03 Million |
|
GHT Co Ltd Class A
SHE:300711
|
$741.11 Million |
|
Jiangsu Tongli Risheng Machinery Co. Ltd.
SHG:605286
|
$741.20 Million |
|
Suzhou Longway Electronic Machinery Co. Ltd. A
SHE:301202
|
$741.30 Million |
|
Golden Entertainment Inc
NASDAQ:GDEN
|
$740.46 Million |
|
Movida Participações S.A
SA:MOVI3
|
$740.46 Million |
|
National Grid PLC
LSE:NG
|
$740.35 Million |
|
Brightspire Capital Inc
NYSE:BRSP
|
$739.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Annexon Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 293,105,000 to 211,648,000, a change of -81,457,000 (-27.8%).
- Net loss of 206,690,000 reduced equity.
- Dividend payments of 1,857,000 reduced retained earnings.
- New share issuances of 109,559,000 increased equity.
- Other comprehensive income decreased equity by 39,000.
- Other factors increased equity by 17,570,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-206.69 Million | -97.66% |
| Dividends Paid | $1.86 Million | -0.88% |
| Share Issuances | $109.56 Million | +51.76% |
| Other Comprehensive Income | $-39.00K | -0.02% |
| Other Changes | $17.57 Million | +8.3% |
| Total Change | $- | -27.79% |
Book Value vs Market Value Analysis
This analysis compares Annexon Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.31x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-1.21 | $4.52 | x |
| 2018-12-31 | $3.31 | $4.52 | x |
| 2019-12-31 | $1.14 | $4.52 | x |
| 2020-12-31 | $20.30 | $4.52 | x |
| 2021-12-31 | $6.05 | $4.52 | x |
| 2022-12-31 | $4.23 | $4.52 | x |
| 2023-12-31 | $3.31 | $4.52 | x |
| 2024-12-31 | $2.13 | $4.52 | x |
| 2025-12-31 | $1.36 | $4.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Annexon Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -97.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.31x
- Recent ROE (-97.66%) is below the historical average (-51.70%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.09 Million |
| 2018 | -48.32% | 0.00% | 0.00x | 1.27x | $-22.09 Million |
| 2019 | -85.42% | 0.00% | 0.00x | 1.15x | $-41.54 Million |
| 2020 | -18.23% | 0.00% | 0.00x | 1.03x | $-97.17 Million |
| 2021 | -55.10% | 0.00% | 0.00x | 1.24x | $-150.98 Million |
| 2022 | -59.82% | 0.00% | 0.00x | 1.23x | $-161.41 Million |
| 2023 | -53.58% | 0.00% | 0.00x | 1.19x | $-159.29 Million |
| 2024 | -47.15% | 0.00% | 0.00x | 1.19x | $-167.51 Million |
| 2025 | -97.66% | 0.00% | 0.00x | 1.31x | $-227.85 Million |
Industry Comparison
This section compares Annexon Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $296,451,843
- Average return on equity (ROE) among peers: -36.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Annexon Inc (ANNX) | $204.53 Million | 0.00% | 0.29x | $740.57 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $81.00 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.55 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $97.37 Million | -71.81% | 0.35x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $33.54 Million |
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -73.87% | 0.28x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $3.59 Billion |
About Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase… Read more